Live Breaking News & Updates on Highlight Symptoms

The Balancing Act® on Lifetime to Feature ENPP1 Deficiency
Educational Episode to Highlight Symptoms of ENPP1 Deficiency and the Importance of Early Diagnosis
BOSTON, March 11, 2021 (GLOBE NEWSWIRE) Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization, announced today that ENPP1 deficiency will be featured on The Balancing Act
® as part of the show’s recurring “Behind the Mystery of Rare and Genetic Diseases” series to raise awareness for this rare, debilitating, and life-threatening mineralization disease for which there are currently no approved treatment options.
The episode will feature Janine Hicks, a patient living with ENPP1 deficiency; her parents, Donna and Peter Hicks; and Professor Zulf Mughal, a treating physician and researcher and Consultant in Pediatric Bone Disorders, Royal Manchester Children’s Hospital, Manchester University NHS Foundatio ....

United States , Peter Hicks , Inozyme Pharma , Christine Obrien , Joseph Schlessinger , Alex Van Rees , Zulf Mughal , Axel Bolte , Janine Hicks , Liz Molloy , Demetrios Braddock , Exchange Commission , Yale University , Manchester University , Inozyme Pharma Inc , Educational Episode , Highlight Symptoms , Professor Zulf Mughal , Pediatric Bone Disorders , Royal Manchester Children , Christineo Brien , Balancing Act , Generalized Arterial Calcification , Hypophosphatemic Rickets , Private Securities Litigation Reform Act , ஒன்றுபட்டது மாநிலங்களில் ,